Skip to main content
Midas Edge

Vanda Pharmaceuticals Inc.

For the period ended Dec 30, 2025. Filed Dec 31, 2025.

View on SEC.gov

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

Dec 30, 2025 · Filed Dec 31, 2025

Use the contents to explore the available documents and sections.

VNDA$3.82+6.4%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

EX-99.1 · References

References

  1. Polymeropoulos VM, Kiely L, Bushman ML, Sutherland EB, Goldberg AR, Pham AX, Miller CR, Mourad R, Davis TR, Pham NV, Morgan DB, Giles AK, Xiao C, Polymeropoulos CM, Birznieks G, Polymeropoulos MH. Motion Syros: tradipitant effective in the treatment of motion sickness; a multicenter, randomized, double-blind, placebo-controlled study. Front Neurol. 2025 Mar 4;16:1550670. doi: 10.3389/fneur.2025.1550670. PMID: 40103934; PMCID: PMC11913704, available here.

  2. Vanda Pharmaceuticals Inc., “Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness” [Press Release], May 16, 2024, available here.

  3. Turner M, Griffin MJ. Motion sickness in public road transport: passenger behavior and susceptibility. Ergonomics. 1999: 42: 444-461, available here.

  4. Golding, J. F. (2016). "Motion sickness". Neuro-Otology. Handbook of Clinical Neurology. Vol. 137. pp. 371–390. doi:10.1016/B978-0-444-63437-5.00027-3. ISBN 978-0-444-63437-5. ISSN 0072-9752. PMID 27638085, available here.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.